EUVIMEDEUVIMED entdecken
Crossref

Association of tumor-infiltrating lymphocytes and proinflammatory biomarkers with breast cancer molecular subtypes: analysis of the MEND study

Jovita Byemerwa, Drew Neish, Lukeman Forgah, April Deveaux, Oyomoare Osazuwa-Peters, Ashwini Joshi, Omolola Salako, Adetola Daramola, Olusegun Alatise, Gabriel Ogun, Allison Hall, Adewale Adeniyi und 12 weitere

Breast Cancer Research and Treatment · 2026-07 · 218 (1)

DOI: 10.1007/s10549-026-08022-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 10.07.2026. Verfasst von Jovita Byemerwa und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA. Hauptthemen laut MEDLINE: Lymphocytes, Tumor-Infiltrating, Biomarkers, Tumor, Breast Neoplasms, Triple Negative Breast Neoplasms. Die Arbeit nennt 85 Literaturangaben. Gefördert von: FIC NIH HHS, National Cancer Institute and the Fogarty International Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Tumor-infiltrating lymphocytes (TILs) and proinflammatory biomarkers shape breast cancer (BC) progression and outcomes. We estimated the association between TILs and BC subtypes in Nigerian women and, in exploratory analyses, evaluated relationships between serum biomarkers (IL-6, IL-8, IL-1β, TNF-α, and leptin), TILs and BC subtypes. METHODS: TILs were quantified on H&E-stained tumors from 436 treatment-naïve Nigerian BC patients, serum biomarkers (n = 109) were profiled by Meso Scale Discovery immunoassays. TILs and proinflammatory biomarkers were assessed across BC subtypes using descriptive analyses and multinomial logistic regression; cytokine ratios were also explored to characterize TNF-α dominance. RESULTS: Median age was 49, and subtypes were triple-negative (TNBC, 43%), luminal A (31%), luminal B (12%), and HER2-enriched (15%). Median TIL percentage was 10.0 (Q1, Q3: 4.0, 21.0), with 49% of patients classified as low TIL (< 10%), 41% as intermediate (10- < 40%) and 10% as high (≥ 40%). Compared to low TILs, medium (OR 1.94, 95% CI 1.11-3.38, p = 0.020) and high TILs (OR 2.65, 95% CI 1.00-6.99, p = 0.049) were associated with higher odds of TNBC vs. ER+ after demographic and clinical adjustments. TNF-α correlated with TILs (ρ: 0.21; p = 0.026) and higher TNF-α:IL-1β (OR 4.16, 95% CI 1.35-12.84) and TNF-α:IL-8 (OR 3.81, 95% CI 1.29-11.23) ratios were associated with TNBC but not HER2 (vs. ER+); individual biomarkers were not associated with subtypes. CONCLUSION: Elevated TILs and TNF-α-dominant profiles are associated with TNBC (vs. ER+) in Nigerian women, highlighting potential immunotherapy relevance in Nigerian TNBC cases and a suggestive prognostic/therapeutic role for TNF-α.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphocytes, Tumor-InfiltratingBiomarkers, TumorBreast NeoplasmsTriple Negative Breast NeoplasmsHumansFemaleMiddle AgedAdultTumor Necrosis Factor-alphaPrognosisAgedReceptors, EstrogenErb-b2 Receptor Tyrosine KinasesCytokinesNigeria

Stichwörter der Autor:innen

Breast cancerProinflammatory biomarkersTNF-αTriple negative breast cancerTumor-associated lymphocytes

Substanzen

Biomarkers, TumorTumor Necrosis Factor-alphaReceptors, EstrogenErb-b2 Receptor Tyrosine KinasesCytokines

Autor:innen und Institutionen

  • Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
  • Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA.
  • College of Medicine & Lagos University Teaching Hospital, University of Lagos, Lagos, Lagos State, Nigeria.
  • College of Medicine, University of Lagos, Lagos, Lagos State, Nigeria.
  • Obafemi Awolowo University Teaching Hospital, Ife-Ife, Osun State, Nigeria.
  • University College Hospital, University of Ibadan, Ibadan, Oyo State, Nigeria.

Förderung

  • FIC NIH HHS
  • National Cancer Institute and the Fogarty International Center

Zitieren

APA

Byemerwa, J., Neish, D., Forgah, L., Deveaux, A., Osazuwa-Peters, O., Joshi, A., Salako, O., Daramola, A., Alatise, O., Ogun, G., Hall, A., Adeniyi, A., Ayandipo, O., Olajide, T., Olasehinde, O., Arowolo, O., Adisa, A., Afuwape, O., Olusanya, A., …, & Akinyemiju, T. (2026). Association of tumor-infiltrating lymphocytes and proinflammatory biomarkers with breast cancer molecular subtypes: analysis of the MEND study. Breast Cancer Research and Treatment, 218(1). https://doi.org/10.1007/s10549-026-08022-3

Vancouver

Byemerwa J, Neish D, Forgah L, Deveaux A, Osazuwa-Peters O, Joshi A, et al. Association of tumor-infiltrating lymphocytes and proinflammatory biomarkers with breast cancer molecular subtypes: analysis of the MEND study. Breast Cancer Research and Treatment. 2026;218(1). doi:10.1007/s10549-026-08022-3

BibTeX
@article{Byemerwa2026,
  author = {Byemerwa, Jovita and Neish, Drew and Forgah, Lukeman and Deveaux, April and Osazuwa-Peters, Oyomoare and Joshi, Ashwini and Salako, Omolola and Daramola, Adetola and Alatise, Olusegun and Ogun, Gabriel and Hall, Allison and Adeniyi, Adewale and Ayandipo, Omobolaji and Olajide, Thomas and Olasehinde, Olalekan and Arowolo, Olukayode and Adisa, Adewale and Afuwape, Oludolapo and Olusanya, Aralola and Adegoke, Aderemi and Tollefsbol, Trygve O and Arnett, Donna and Muehlbauer, Michael J and Akinyemiju, Tomi},
  title = {Association of tumor-infiltrating lymphocytes and proinflammatory biomarkers with breast cancer molecular subtypes: analysis of the MEND study},
  journal = {Breast Cancer Research and Treatment},
  year = {2026},
  volume = {218},
  number = {1},
  doi = {10.1007/s10549-026-08022-3}
}
Kostenlos starten →